| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/09/2002 | EP1169030A1 Agents and methods for promoting production gains in animals |
| 01/09/2002 | EP1169026A2 Use of ap-1 activators to treat glaucoma and ocular hypertension |
| 01/09/2002 | EP1169005A2 Association of no-synthase inhibitor(s) and metabolic antioxidant(s) |
| 01/09/2002 | EP1168997A1 Vacuum assisted closure system with provision for introduction of agent |
| 01/09/2002 | EP1168919A2 Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion |
| 01/09/2002 | EP1168917A2 Human lung cancer associated gene sequences and polypeptides |
| 01/09/2002 | EP1168912A1 Organ arrest, protection and preservation |
| 01/09/2002 | EP0984699A4 Method of inhibiting immune system destruction of transplanted viable cells |
| 01/09/2002 | EP0765151B1 Antibacterial oil-in-water emulsions |
| 01/09/2002 | EP0727978B1 Topical aromatic releasing compositions |
| 01/09/2002 | CN1330675A Polyamide chains of precise length, methods to manufacture them and their conjugates with protein |
| 01/09/2002 | CN1330664A Platelet-derived growth factor C, DNA coding therefor and uses thereof |
| 01/09/2002 | CN1330637A Compounds useful in treatment of infammatory diseases |
| 01/09/2002 | CN1330636A Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives having 5HT1A receptor activity |
| 01/09/2002 | CN1330556A Combination therepy of angiotensin-converting enzyme inhibor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
| 01/09/2002 | CN1330550A Use of substances with oxytocin activity in order to create cell regeneration |
| 01/09/2002 | CN1330543A Compositions and methods for amelioration of human female sexual dysfunction |
| 01/09/2002 | CN1330540A Utilization of inhibitors of KQT1 channel in order to produce medicament for treating diseases which are caused by parasitic helminths and actoparasites |
| 01/09/2002 | CN1330539A Compositions and methods for treatment of anorectal disorders |
| 01/09/2002 | CN1330538A Stable pharmaceutical formulation comprising HMC-CoA reductase inhibitor |
| 01/09/2002 | CN1330536A Biodegradable polymer encapsulated 5-hydroxytryptamine receptor antagonist and method for preparing the same |
| 01/09/2002 | CN1330532A Oil-in-water emulsion comprising micronised biologically active agent and appropriate emulsified system |
| 01/08/2002 | US6337348 Inhibiting motility of sperm with oxovanadium compound with 1,10-phenanthroline, 2,2'bipyridine, 2'hydroxyacetophenone or 3-hydroxypropenal for complexes |
| 01/08/2002 | US6337328 Bupropion metabolites and methods of use |
| 01/08/2002 | US6337327 Drugs for enzyme inhibiting such as angiotensin converting enzyme |
| 01/08/2002 | US6337325 Combined preparation for the therapy of immune diseases |
| 01/08/2002 | US6337324 Pharmaceutical combination |
| 01/08/2002 | US6337321 Treaatment of cardiovascular disorders in mammals |
| 01/08/2002 | US6337317 Amino acid sequence peptides as microbiocides |
| 01/08/2002 | US6337094 Bioavailability |
| 01/08/2002 | US6337076 Applying onto hypertrophic scar a liquid formulation comprising collodion film-forming carrier having dermatologically effective amount of active ingredient capable of reducing size of scar or improving appearance |
| 01/08/2002 | US6337075 Methods for treating diabetes |
| 01/07/2002 | CA2582179A1 Methods for identifying combinations of entities as therapeutics |
| 01/03/2002 | WO2002000913A2 MODULATION OF β-AMYLOID LEVELS BY β-SECRETASE BACE2 |
| 01/03/2002 | WO2002000873A1 Human site-1 protease promoter |
| 01/03/2002 | WO2002000860A2 Novel proteases |
| 01/03/2002 | WO2002000840A2 Human lyases |
| 01/03/2002 | WO2002000839A2 Statement as to federally sponsored research |
| 01/03/2002 | WO2002000724A2 Thymic stromal lymphopoietin receptor molecules and uses thereof |
| 01/03/2002 | WO2002000715A2 Mammal 2p domain mechano-sensitive k+ channel, cloning and applications thereof |
| 01/03/2002 | WO2002000713A1 Prion-binding activity in serum and plasma determined as plasminogen and fibrinogen |
| 01/03/2002 | WO2002000711A2 Ev-vegf nucleic acids and polypeptides and methods of use |
| 01/03/2002 | WO2002000687A2 Antimicrobial peptides and methods of use thereof |
| 01/03/2002 | WO2002000661A1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
| 01/03/2002 | WO2002000617A2 Selective androgen receptor modulators and methods for their identification, design and use |
| 01/03/2002 | WO2002000269A1 The use of honey in wound dressings |
| 01/03/2002 | WO2002000266A2 A method of treating and preventing infectious diseases |
| 01/03/2002 | WO2002000254A2 Materials and methods relating for the treatment and diagnosis of pre-eclampsia |
| 01/03/2002 | WO2002000244A2 Protein mixtures for wound healing |
| 01/03/2002 | WO2002000233A2 Purging of cells using viruses |
| 01/03/2002 | WO2002000218A2 Methods of treating neutrophil-related diseases with topical anesthetics |
| 01/03/2002 | WO2002000210A2 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease |
| 01/03/2002 | WO2002000203A1 Topical pharmaceutical formulations and methods of treatment |
| 01/03/2002 | WO2002000201A2 Method for preparing a composition |
| 01/03/2002 | WO2002000195A2 Methods and compositions for treating pain of the mucous membrane |
| 01/03/2002 | WO2002000175A2 Enhancing therapeutic effectiveness of nitric oxide inhalation |
| 01/03/2002 | WO2002000170A2 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
| 01/03/2002 | WO2002000168A2 Combination hiv therapy including camptothecin |
| 01/03/2002 | WO2002000166A2 New compounds useful as antibacterial agents |
| 01/03/2002 | WO2002000161A1 Medicinal product package for eradication therapy |
| 01/03/2002 | WO2002000024A1 New strategy for leukemia therapy |
| 01/03/2002 | WO2002000017A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/03/2002 | WO2001066601A8 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals |
| 01/03/2002 | WO2001058472A3 Botulinum toxin pharmaceutical compositions |
| 01/03/2002 | WO2001055336A3 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/03/2002 | WO2001053344A3 Chondromodulin-i related peptide |
| 01/03/2002 | WO2001049314A3 Glp-2 formulations |
| 01/03/2002 | WO2001046383A3 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein |
| 01/03/2002 | WO2001045836A3 Molecules derived from mechanism based drug design |
| 01/03/2002 | WO2001045676A3 Extended release oral dosage composition |
| 01/03/2002 | WO2001035979A3 Combined pde3 and pde4 inhibitor therapy for the treatment of obesity |
| 01/03/2002 | WO2001035935A3 Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer |
| 01/03/2002 | WO2001032877A3 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 01/03/2002 | WO2001028587A3 Magnetic targeted carrier |
| 01/03/2002 | WO2001024826A3 Inrease of enos activity through activation of the pi3-kinase/akt pathway by estrogens |
| 01/03/2002 | WO2001015678A3 Topical use of kappa opioid agonists to treat otic pain |
| 01/03/2002 | WO2000061171A9 Uses of mammalian ox2 protein and related reagents |
| 01/03/2002 | US20020002197 Tropisetron, Fabesetron, Ramosetron and other drugs useful for treatment of a non-inflammatory local disease of the musculo-sceletal system, of a local irritation condition of a joint or tendom sheath or local manifestation |
| 01/03/2002 | US20020002194 Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| 01/03/2002 | US20020002186 Pharmaceutical composition |
| 01/03/2002 | US20020002180 A synergistic mixture of lamivudine and BMS-200475 for the treatment of a Hepititis B viral infection; effective against mutants resistant to nucleoside and/or non-nucleoside inhibitors of the replication of the HBV |
| 01/03/2002 | US20020002178 Antiproliferative, -carcinogenic agents, antiinflammatory and -arthritis agents; neurodegenerative diseases, e.g., Alzheimer's disease; cardiovascular disorders; viricides; fungicides |
| 01/03/2002 | US20020002176 Apomorphine and norapomorphine N-glucuronides, O-sulfates, O-glucuronides, N-sulfates, O-phosphates and N-phosphates, esters, ethers, and N-alkyls; sexual disorders and Parkinson's disease; bioavailability; side effect reduction |
| 01/03/2002 | US20020002166 Use of MKC-442 in combination with other antiviral agents |
| 01/03/2002 | US20020002165 Growth hormone secretagogues useful for treatment/prevention of osteoporosis |
| 01/03/2002 | US20020002162 Synergistic methods and compositions for treating cancer |
| 01/03/2002 | US20020002159 Use of beta-lactamase inhibitors as neuroprotectants |
| 01/03/2002 | US20020002149 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors |
| 01/03/2002 | US20020002147 Stabilizing amount of magnesium stearate; extended dosage formed by extrusion and spheronization and coated with a seal coating; nucleoside reverse transcriptase inhibitor; treatment of retroviruses, HIV |
| 01/03/2002 | US20020002145 Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver |
| 01/03/2002 | US20020002142 Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation |
| 01/03/2002 | US20020002137 Combination of growth hormone secretagogues and antidepressants |
| 01/03/2002 | US20020002135 Pharmaceutical use |
| 01/03/2002 | US20020002134 PAI-2 conjugates for the treatment and imaging of cancer |
| 01/03/2002 | US20020001840 Methods and compositions for modulating integrin-mediated cell-cell interactions |
| 01/03/2002 | US20020001585 Administering a blocking agent of tumor necrosis factors or receptors; treatment of Sin Nombre (SNV), Ebola, Marburg, Lassa, and Dengue viral disease |
| 01/03/2002 | US20020001575 Nutritional system for nervous system disorders |
| 01/03/2002 | US20020001566 Pharmaceuticals for the imaging of angiogenic disorders |
| 01/03/2002 | US20020001332 Mounting arrangement for auxiliary burner or lance |
| 01/03/2002 | DE10027514A1 Liganden von Integrinrezeptoren Ligands of integrin |